CL2013001712A1 - Compuestos derivados de n-(1h-indazol-4-il)imidazo[1,2-a]piridin-3-carboxamida, inhbidores de la tirosina quinasa receptora de tipo iii; proceso de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades inflamatorias, cardiovasculares, fibrosis, trastornos autoinmunes, dolor, quemaduras. - Google Patents

Compuestos derivados de n-(1h-indazol-4-il)imidazo[1,2-a]piridin-3-carboxamida, inhbidores de la tirosina quinasa receptora de tipo iii; proceso de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades inflamatorias, cardiovasculares, fibrosis, trastornos autoinmunes, dolor, quemaduras.

Info

Publication number: CL2013001712A1
Authority: CL; Chile
Prior art keywords: indazol; imidazo; carboxamide; pyridin; fibrosis
Prior art date: 2010-12-13

Application number

CL2013001712A

Other languages

English (en)

Inventor

Zhao Qian

Laurence Boys Mark

Kirk Delisle Robert

James Hicken Erik

L Kennedy April

A Mareska David

P Marmsater Fredrik

c munson Mark

Newhouse Brad

Rast Bryson

P Rizzi James

E Rodriguez Martha

T Topalov George

Original Assignee

Array Biopharma Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-12-13

Filing date

2013-06-13

Publication date

2013-12-06

2013-06-13 Application filed by Array Biopharma Inc filed Critical Array Biopharma Inc

2013-12-06 Publication of CL2013001712A1 publication Critical patent/CL2013001712A1/es

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Immunology (AREA)
Physical Education & Sports Medicine (AREA)
Hematology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Obesity (AREA)
Dermatology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Transplantation (AREA)
Diabetes (AREA)
Oncology (AREA)
Biomedical Technology (AREA)
Pulmonology (AREA)
Heart & Thoracic Surgery (AREA)
Orthopedic Medicine & Surgery (AREA)
Cardiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

CL2013001712A 2010-12-13 2013-06-13 Compuestos derivados de n-(1h-indazol-4-il)imidazo[1,2-a]piridin-3-carboxamida, inhbidores de la tirosina quinasa receptora de tipo iii; proceso de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades inflamatorias, cardiovasculares, fibrosis, trastornos autoinmunes, dolor, quemaduras. CL2013001712A1 (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US42254710P	2010-12-13	2010-12-13

Publications (1)

Publication Number	Publication Date
CL2013001712A1 true CL2013001712A1 (es)	2013-12-06

Family

ID=45478484

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CL2013001712A CL2013001712A1 (es)	2010-12-13	2013-06-13	Compuestos derivados de n-(1h-indazol-4-il)imidazo[1,2-a]piridin-3-carboxamida, inhbidores de la tirosina quinasa receptora de tipo iii; proceso de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades inflamatorias, cardiovasculares, fibrosis, trastornos autoinmunes, dolor, quemaduras.

Country Status (32)

Country	Link
US (3)	US9174981B2 (es)
EP (1)	EP2651939B1 (es)
JP (3)	JP5868996B2 (es)
KR (1)	KR101974665B1 (es)
CN (3)	CN105924437B (es)
AU (3)	AU2011344001B2 (es)
BR (1)	BR112013014854B1 (es)
CA (2)	CA3027814A1 (es)
CL (1)	CL2013001712A1 (es)
CO (1)	CO6751248A2 (es)
CR (1)	CR20130349A (es)
DK (1)	DK2651939T3 (es)
ES (1)	ES2540996T3 (es)
HR (1)	HRP20150571T1 (es)
HU (1)	HUE025416T2 (es)
IL (1)	IL226911A (es)
ME (1)	ME02172B (es)
MX (1)	MX2013006763A (es)
MY (1)	MY172110A (es)
NZ (1)	NZ613235A (es)
PH (1)	PH12013501221A1 (es)
PL (1)	PL2651939T3 (es)
PT (1)	PT2651939E (es)
RS (1)	RS54070B1 (es)
RU (1)	RU2591195C2 (es)
SG (1)	SG191129A1 (es)
SI (1)	SI2651939T1 (es)
SM (1)	SMT201500165B (es)
TW (1)	TWI527813B (es)
UA (1)	UA112425C2 (es)
UY (1)	UY33801A (es)
WO (1)	WO2012082689A1 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN102822170B (zh) *	2009-12-21	2014-12-10	阵列生物制药公司	作为cFMS抑制剂的取代的N-(1H-吲唑-4-基)咪唑并[1,2-a]吡啶-3-羧酰胺化合物
PT2651939E (pt)	2010-12-13	2015-08-04	Array Biopharma Inc	Compostos n-(1h-indazol-4-il)imidazo[1,2-a]piridina-3- carboxamida substituídos enquanto inibidores de tirosina quinase de receptores de tipo iii
GB201315486D0 (en) *	2013-08-30	2013-10-16	Ucb Pharma Sa	Antibodies
JO3517B1 (ar)	2014-01-17	2020-07-05	Novartis Ag	ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
CN104496891A (zh) *	2014-12-06	2015-04-08	哈尔滨工业大学	吡啶衍生物2-叔丁氧基-6-亚甲基氯吡啶的合成方法
CN104974078A (zh) *	2015-06-25	2015-10-14	黄荣辉	一种2-甲基-6-氯甲基吡啶盐酸盐的制备方法
US10836742B2 (en)	2015-08-11	2020-11-17	Neomed Institute	N-substituted bicyclic lactams, their preparation and their use as pharmaceuticals
CN108290856A (zh)	2015-08-11	2018-07-17	尼奥迈德研究所	芳基-取代的二氢喹诺酮、它们的制备和它们作为药物的用途
KR102784592B1 (ko)	2015-08-12	2025-03-19	에피제네틱스, 인크.	치환된 벤즈이미다졸, 그의 제조법 및 제약으로서의 그의 용도
WO2017066876A1 (en)	2015-10-21	2017-04-27	Neomed Institute	Substituted imidazopyridines, their preparation and their use as pharmaceuticals
US10889564B2 (en)	2015-11-02	2021-01-12	Genase Therapeutics B.V.	Tetrahydroindazoles and medical uses thereof
CN105198799A (zh) *	2015-11-03	2015-12-30	江苏梦得电镀化学品有限公司	一种2-甲基-6-氯甲基吡啶盐酸盐的制备方法
US10519151B2 (en)	2016-01-28	2019-12-31	Neomed Institute	Substituted [1,2,4]triazolo[4,3-A]pyridines, their preparation and their use as pharmaceuticals
US10934285B2 (en) *	2016-06-14	2021-03-02	Novartis Ag	Compounds and compositions for inhibiting the activity of SHP2
CN106187899B (zh) *	2016-06-28	2019-07-16	绍兴文理学院	一种氟代氮杂芳烃的合成方法
CN109790079B (zh) *	2016-07-29	2022-06-03	香港科技大学	有机锌试剂与杂环(拟)卤化物的C(sp3)-C(sp2)交叉偶联反应
AU2017355603A1 (en)	2016-11-04	2019-06-20	Auckland Uniservices Limited	Tricyclic heterocyclic derivatives and uses thereof
KR102425785B1 (ko) *	2016-11-28	2022-07-28	에자이 알앤드디 매니지먼트 가부시키가이샤	인다졸 유도체의 염 및 이의 결정
WO2018213665A1 (en)	2017-05-19	2018-11-22	Syndax Pharmaceuticals, Inc.	Combination therapies
SI3658552T1 (sl)	2017-07-28	2023-11-30	Yuhan Corporation	Postopek za pripravo N-(5-((4-(4-((dimetilamino)metil)-3-fenil-1H-pirazol-1-il)pirimidin-2-il )amino)-4-metoksi-2-morfolinofenil)akrilamida z reagiranjem ustreznega amina s 3-halo-propionil kloridom
EP3765459A1 (en)	2018-03-13	2021-01-20	Shire Human Genetic Therapies, Inc.	Substituted imidazopyridines as inhibitors of plasma kallikrein and uses thereof
CN111410654B (zh) *	2019-01-19	2022-05-17	江苏新元素医药科技有限公司	3-溴-5-(2-乙基咪唑并[1,2-a]吡啶-3-羰基)-2-羟基苯甲腈的合成
TWI841671B (zh)	2019-01-24	2024-05-11	日商第一三共股份有限公司	具有取代基之脲化合物
TWI759829B (zh)	2019-08-23	2022-04-01	財團法人生物技術開發中心	作為第iii型受體酪胺酸激酶抑制劑之雜環吡唑衍生物
JP7695232B2 (ja)	2019-09-18	2025-06-18	武田薬品工業株式会社	ヘテロアリール血漿カリクレインインヒビター
US11787796B2 (en)	2019-09-18	2023-10-17	Takeda Pharmaceutical Company Limited	Plasma Kallikrein inhibitors and uses thereof
WO2025146196A1 (zh) *	2024-01-04	2025-07-10	上海翰森生物医药科技有限公司	多环类衍生物抑制剂、其制备方法和应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5543523A (en)	1994-11-15	1996-08-06	Regents Of The University Of Minnesota	Method and intermediates for the synthesis of korupensamines
EP1511742B1 (en)	2002-05-23	2010-02-03	Cytopia Research Pty Ltd	Kinase inhibitors
JP5442449B2 (ja) *	2006-12-22	2014-03-12	アステックス、セラピューティックス、リミテッド	新規化合物
KR101538179B1 (ko) *	2007-04-03	2015-07-20	어레이 바이오파마 인크.	수용체 티로신 키나제 억제제로서의 이미다조[1,2-ａ]피리딘 화합물
FR2925901B1 (fr)	2008-01-02	2011-03-04	Sanofi Aventis	DERIVES DE N-HETEROCYCLIQUE-IMIDAZO°1,2-a!PYRIDINE-2- CARBOXAMIDES, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE
WO2009147189A1 (en)	2008-06-05	2009-12-10	Glaxo Group Limited	Novel compounds
TW201105669A (en) *	2009-07-30	2011-02-16	Irm Llc	Compounds and compositions as Syk kinase inhibitors
CN102822170B (zh) *	2009-12-21	2014-12-10	阵列生物制药公司	作为cFMS抑制剂的取代的N-(1H-吲唑-4-基)咪唑并[1,2-a]吡啶-3-羧酰胺化合物
PT2651939E (pt) *	2010-12-13	2015-08-04	Array Biopharma Inc	Compostos n-(1h-indazol-4-il)imidazo[1,2-a]piridina-3- carboxamida substituídos enquanto inibidores de tirosina quinase de receptores de tipo iii
JO3337B1 (ar)	2010-12-13	2019-03-13	Debiopharm Sa	تركيبات صيدلية تشمل أليسبوريفير
CN102250246A (zh) *	2011-06-10	2011-11-23	常州亚当生物技术有限公司	抗VEGF/PDGFRβ双特异性抗体及其应用

2011
- 2011-12-13 PT PT118084276T patent/PT2651939E/pt unknown
- 2011-12-13 US US13/994,048 patent/US9174981B2/en not_active Expired - Fee Related
- 2011-12-13 MX MX2013006763A patent/MX2013006763A/es active IP Right Grant
- 2011-12-13 CN CN201610248287.9A patent/CN105924437B/zh not_active Expired - Fee Related
- 2011-12-13 UY UY0001033801A patent/UY33801A/es not_active Application Discontinuation
- 2011-12-13 AU AU2011344001A patent/AU2011344001B2/en not_active Ceased
- 2011-12-13 ES ES11808427.6T patent/ES2540996T3/es active Active
- 2011-12-13 CA CA3027814A patent/CA3027814A1/en not_active Abandoned
- 2011-12-13 ME MEP-2015-98A patent/ME02172B/me unknown
- 2011-12-13 SI SI201130508T patent/SI2651939T1/sl unknown
- 2011-12-13 CN CN201180067342.XA patent/CN103347882B/zh not_active Expired - Fee Related
- 2011-12-13 HU HUE11808427A patent/HUE025416T2/en unknown
- 2011-12-13 PH PH1/2013/501221A patent/PH12013501221A1/en unknown
- 2011-12-13 CA CA2821712A patent/CA2821712C/en not_active Expired - Fee Related
- 2011-12-13 BR BR112013014854-3A patent/BR112013014854B1/pt not_active IP Right Cessation
- 2011-12-13 SG SG2013045349A patent/SG191129A1/en unknown
- 2011-12-13 DK DK11808427.6T patent/DK2651939T3/en active
- 2011-12-13 TW TW100146108A patent/TWI527813B/zh not_active IP Right Cessation
- 2011-12-13 RU RU2013132758/04A patent/RU2591195C2/ru active
- 2011-12-13 CN CN201811311712.XA patent/CN109608449A/zh active Pending
- 2011-12-13 JP JP2013544674A patent/JP5868996B2/ja not_active Expired - Fee Related
- 2011-12-13 NZ NZ61323511A patent/NZ613235A/en not_active IP Right Cessation
- 2011-12-13 KR KR1020137018492A patent/KR101974665B1/ko not_active Expired - Fee Related
- 2011-12-13 MY MYPI2013700991A patent/MY172110A/en unknown
- 2011-12-13 RS RS20150446A patent/RS54070B1/sr unknown
- 2011-12-13 EP EP11808427.6A patent/EP2651939B1/en active Active
- 2011-12-13 WO PCT/US2011/064549 patent/WO2012082689A1/en not_active Ceased
- 2011-12-13 UA UAA201308896A patent/UA112425C2/uk unknown
- 2011-12-13 HR HRP20150571TT patent/HRP20150571T1/hr unknown
- 2011-12-13 PL PL11808427T patent/PL2651939T3/pl unknown
2013
- 2013-06-13 CL CL2013001712A patent/CL2013001712A1/es unknown
- 2013-06-13 IL IL226911A patent/IL226911A/en active IP Right Grant
- 2013-07-15 CO CO13167580A patent/CO6751248A2/es active IP Right Grant
- 2013-07-15 CR CR20130349A patent/CR20130349A/es unknown
2015
- 2015-07-08 SM SM201500165T patent/SMT201500165B/xx unknown
- 2015-09-18 US US14/858,029 patent/US9809590B2/en not_active Expired - Fee Related
- 2015-10-19 JP JP2015205806A patent/JP2016040303A/ja not_active Withdrawn
2016
- 2016-09-02 AU AU2016222468A patent/AU2016222468B2/en not_active Ceased
2017
- 2017-09-27 US US15/717,700 patent/US10669269B2/en not_active Expired - Fee Related
- 2017-11-27 JP JP2017227134A patent/JP2018065835A/ja not_active Withdrawn
2018
- 2018-03-16 AU AU2018201903A patent/AU2018201903B2/en not_active Ceased

Also Published As

Publication number	Publication date
PL2651939T3 (pl)	2015-10-30
CA3027814A1 (en)	2012-06-21
SI2651939T1 (sl)	2015-07-31
CO6751248A2 (es)	2013-09-16
ES2540996T3 (es)	2015-07-15
SMT201500165B (it)	2015-09-07
AU2018201903B2 (en)	2019-09-19
US20130274244A1 (en)	2013-10-17
US20160002232A1 (en)	2016-01-07
CN109608449A (zh)	2019-04-12
KR20140014109A (ko)	2014-02-05
CA2821712C (en)	2019-02-12
US9174981B2 (en)	2015-11-03
RU2013132758A (ru)	2015-01-20
MX2013006763A (es)	2014-01-08
TW201305156A (zh)	2013-02-01
MY172110A (en)	2019-11-14
HUE025416T2 (en)	2016-02-29
US9809590B2 (en)	2017-11-07
PH12013501221A1 (en)	2022-03-30
CR20130349A (es)	2013-08-09
BR112013014854B1 (pt)	2020-12-08
JP5868996B2 (ja)	2016-02-24
PT2651939E (pt)	2015-08-04
RS54070B1 (sr)	2015-10-30
KR101974665B1 (ko)	2019-05-02
US10669269B2 (en)	2020-06-02
AU2018201903A1 (en)	2018-04-12
CN103347882B (zh)	2016-05-11
NZ613235A (en)	2015-04-24
WO2012082689A1 (en)	2012-06-21
JP2013545808A (ja)	2013-12-26
HK1190709A1 (en)	2014-07-11
JP2016040303A (ja)	2016-03-24
US20180086758A1 (en)	2018-03-29
BR112013014854A8 (pt)	2018-03-27
IL226911A (en)	2016-09-29
AU2016222468A1 (en)	2016-09-22
RU2591195C2 (ru)	2016-07-10
JP2018065835A (ja)	2018-04-26
HRP20150571T1 (xx)	2015-07-03
ME02172B (me)	2015-10-20
AU2011344001B2 (en)	2016-06-30
DK2651939T3 (en)	2015-06-01
UY33801A (es)	2013-06-28
TWI527813B (zh)	2016-04-01
EP2651939A1 (en)	2013-10-23
BR112013014854A2 (pt)	2016-10-18
UA112425C2 (uk)	2016-09-12
EP2651939B1 (en)	2015-04-08
CN105924437B (zh)	2018-11-30
SG191129A1 (en)	2013-07-31
CA2821712A1 (en)	2012-06-21
AU2016222468B2 (en)	2017-12-21
CN105924437A (zh)	2016-09-07
CN103347882A (zh)	2013-10-09

Publication	Publication Date	Title
CL2013001712A1 (es)	2013-12-06	Compuestos derivados de n-(1h-indazol-4-il)imidazo[1,2-a]piridin-3-carboxamida, inhbidores de la tirosina quinasa receptora de tipo iii; proceso de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades inflamatorias, cardiovasculares, fibrosis, trastornos autoinmunes, dolor, quemaduras.
CL2007002708A1 (es)	2008-04-04	Compuestos derivados de pirrolo[2,3-b]piridina; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, caquexia, trastornos inflamatorios, entre otros.
JOP20200222A1 (ar)	2022-10-30	أشكال كريستالين لمثبط أنزيم كيناز تيروسين بروتون
DK2321321T3 (da)	2012-05-21	Triazolo [4,5-d]pyramidinderivater og anvendelse deraf som purinreceptorantagonister
WO2012050923A3 (en)	2012-07-19	Engineered polypeptides having enhanced duration of action
WO2014022116A3 (en)	2015-07-16	Substituted pyrazolone compounds and methods of use
UA95940C2 (uk)	2011-09-26	Азаіндоли як інгібітори кіназ януса
CR8642A (es)	2008-11-28	Compuestos, composiciones farmaceuticas y metodos para su uso en el tratameinto de desordenes metabolicos
CR20120389A (es)	2012-08-16	COMPUESTOS SUSTITUIDOS DE N-(1H-INDAZOL-4-IL)IMIDAZO[1,2-a] PIRIDIN-3-CARBOXAMIDA COMO INHIBIDORES DE cFMS
MY167575A (en)	2018-09-20	Heterocyclic compounds and use thereof as modulators of type iii receptor tyrosine kinases
SMT201600164B (it)	2016-07-01	Nuove n-acil-5, 6, 7, ( 8-s0stituito )-tetraidro-[1, 2, 4]triazolo[4, 3-a]pirazine chirali come antagonisti selettivi del recettore nk-3, composizione farmaceutica, e metodi per l'uso in disturbi mediati dal recettore nk-3
MX2009008253A (es)	2009-10-12	Derivados de 2-aminopiridina utiles como inhibidores de cinasa.
EA201390803A1 (ru)	2013-09-30	Ингибиторы бромодомена и их применение
MX2009006700A (es)	2009-06-30	Derivados de 5-ciano-4-(pirolo)[2,3b]piridina-3-il)-pirimidinas utiles como inhibidores de proteina-cinasas.
WO2010011772A3 (en)	2010-04-29	Tri-cyclic pyrazolopyridine kinase inhibitors
EA201000797A1 (ru)	2011-02-28	Аминотриазолы в качестве ингибиторов pi3k
DK1812440T3 (da)	2011-01-31	Pyrazolo[1,5-a]pyrimidiner, der kan anvendes som inhibistorer af proteinkinaser
CL2008001025A1 (es)	2008-10-17	Compuestos derivados de pirimido[5,4-d]pirimidina-2,4,6,8-tetraona; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como trastorno metabolico, dislipidemia y cancer.
CL2008000905A1 (es)	2008-08-22	Compuestos derivados de morfina, antagonistas del receptor opioide periferico; metodo de preparacion; composicion farmaceutica; y uso para reducir los efectos de la actividad opioide endogena.
LT3135672T (lt)	2020-05-25	Kompozicijos ir būdai skirti gydyti alkoholio vartojimo sutrikimus, skausmą ir kitas ligas
CL2011000116A1 (es)	2011-06-17	Compuestos derivados de imidazo[1,2-a]piridina; procedimiento de preparacion; composicion farmaceutica; compuestos intermediarios; y uso en el tratamiento del cancer.
WO2008018827A8 (en)	2009-02-19	Benzimidazole derivatives useful in treatment of vallinoid receptor trpv1 related disorders
EA201190017A1 (ru)	2012-02-28	Аминоэфирные производные алкалоидов и их медицинские композиции
EA201270087A1 (ru)	2012-07-30	Твердые фармацевтические композиции с фиксированной дозой, содержащие ирбесартан и амлодипин, их получение и их терапевтическое применение
FR2925902B1 (fr)	2011-01-07	DERIVES D'IMIDAZO°1,2-a!PYRIDINE-2-CARBOXAMIDES, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE